Last reviewed · How we verify

L-BUPIVACAINE ; MORPHINE

Corporacion Parc Tauli · Phase 3 active Small molecule

This combination uses L-bupivacaine (a local anesthetic) and morphine (an opioid analgesic) to provide regional anesthesia and postoperative pain relief through blockade of nerve conduction and opioid receptor activation.

This combination uses L-bupivacaine (a local anesthetic) and morphine (an opioid analgesic) to provide regional anesthesia and postoperative pain relief through blockade of nerve conduction and opioid receptor activation. Used for Postoperative pain management, Regional anesthesia with systemic analgesia.

At a glance

Generic nameL-BUPIVACAINE ; MORPHINE
Also known asPERIDURAL L-BUPIVACAINE, PCA MORPHINE
SponsorCorporacion Parc Tauli
Drug classLocal anesthetic + opioid analgesic combination
TargetVoltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhasePhase 3

Mechanism of action

L-bupivacaine is the active S-enantiomer of bupivacaine that blocks sodium channels in nerve fibers, preventing pain signal transmission when administered locally or regionally. Morphine acts systemically as a mu-opioid receptor agonist to provide additional analgesia. The combination is designed to provide both local anesthetic effect and systemic opioid analgesia for perioperative pain management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: